Published in Brain on August 01, 2002
Impaired small-world efficiency in structural cortical networks in multiple sclerosis associated with white matter lesion load. Brain (2009) 2.28
Gray matter atrophy correlates with MS disability progression measured with MSFC but not EDSS. J Neurol Sci (2008) 1.90
Sample sizes for brain atrophy outcomes in trials for secondary progressive multiple sclerosis. Neurology (2008) 1.80
New multispectral MRI data fusion technique for white matter lesion segmentation: method and comparison with thresholding in FLAIR images. Eur Radiol (2010) 1.76
Optical coherence tomography in multiple sclerosis: thickness of the retinal nerve fiber layer as a potential measure of axonal loss and brain atrophy. J Neurol (2008) 1.75
Spinal cord repair in MS: does mitochondrial metabolism play a role? Neurology (2010) 1.56
Rostrocaudal analysis of corpus callosum demyelination and axon damage across disease stages refines diffusion tensor imaging correlations with pathological features. J Neuropathol Exp Neurol (2010) 1.50
Spinal cord gray matter atrophy correlates with multiple sclerosis disability. Ann Neurol (2014) 1.50
Mechanisms of neurodegeneration and axonal dysfunction in multiple sclerosis. Nat Rev Neurol (2014) 1.46
Pharmacogenomics of interferon-beta therapy in multiple sclerosis: baseline IFN signature determines pharmacological differences between patients. PLoS One (2008) 1.43
Brain viscoelasticity alteration in chronic-progressive multiple sclerosis. PLoS One (2012) 1.41
Assessing structure and function of the afferent visual pathway in multiple sclerosis and associated optic neuritis. J Neurol (2009) 1.29
MRI evidence for multiple sclerosis as a diffuse disease of the central nervous system. J Neurol (2005) 1.26
Biomarkers and surrogate outcomes in neurodegenerative disease: lessons from multiple sclerosis. NeuroRx (2004) 1.23
Corticospinal tract abnormalities are associated with weakness in multiple sclerosis. AJNR Am J Neuroradiol (2007) 1.17
Recovery after spinal cord relapse in multiple sclerosis is predicted by radial diffusivity. Mult Scler (2010) 1.14
TASK1 modulates inflammation and neurodegeneration in autoimmune inflammation of the central nervous system. Brain (2009) 1.09
Quantification and clinical relevance of brain atrophy in multiple sclerosis: a review. J Neurol (2009) 1.08
Brain magnetic resonance imaging in newly diagnosed systemic lupus erythematosus. J Rheumatol (2008) 1.07
Genetic algorithms for finite mixture model based voxel classification in neuroimaging. IEEE Trans Med Imaging (2007) 1.07
MR spectroscopy indicates diffuse multiple sclerosis activity during remission. J Neurol Neurosurg Psychiatry (2009) 1.07
Metabolic changes in the visual cortex are linked to retinal nerve fiber layer thinning in multiple sclerosis. PLoS One (2011) 1.06
Energy failure in multiple sclerosis and its investigation using MR techniques. J Neurol (2011) 1.06
Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis-clinical implementation in the diagnostic process. Nat Rev Neurol (2015) 1.04
Recommendations to improve imaging and analysis of brain lesion load and atrophy in longitudinal studies of multiple sclerosis. J Neurol (2012) 1.04
Gray matter imaging in multiple sclerosis: what have we learned? BMC Neurol (2011) 1.03
In vivo evidence of disseminated subpial T2* signal changes in multiple sclerosis at 7 T: a surface-based analysis. Neuroimage (2011) 1.03
The effect of hypointense white matter lesions on automated gray matter segmentation in multiple sclerosis. Hum Brain Mapp (2011) 1.01
Correlation between brain volume loss and clinical and MRI outcomes in multiple sclerosis. Neurology (2015) 1.01
Imaging of multiple sclerosis: role in neurotherapeutics. NeuroRx (2005) 0.98
Effects of delayed-release dimethyl fumarate on MRI measures in the Phase 3 DEFINE study. J Neurol (2014) 0.97
Assessing neuronal metabolism in vivo by modeling imaging measures. J Neurosci (2010) 0.97
Tracking changes following spinal cord injury: insights from neuroimaging. Neuroscientist (2012) 0.94
MRI quantification of gray and white matter damage in patients with early-onset multiple sclerosis. J Neurol (2006) 0.91
Cross-validation of brain segmentation by SPM5 and SIENAX. Psychiatry Res (2008) 0.91
Accurate GM atrophy quantification in MS using lesion-filling with co-registered 2D lesion masks. Neuroimage Clin (2014) 0.91
Sensitivity and reproducibility of a new fast 3D segmentation technique for clinical MR-based brain volumetry in multiple sclerosis. Neuroradiology (2004) 0.89
Predictive value of early brain atrophy on response in patients treated with interferon β. Neurol Neuroimmunol Neuroinflamm (2015) 0.89
Elevated intrathecal antibodies against the medium neurofilament subunit in multiple sclerosis. J Neurol (2007) 0.88
Cortical atrophy in experimental autoimmune encephalomyelitis: in vivo imaging. Neuroimage (2011) 0.88
Automatic Counting of Microglial Cells in Healthy and Glaucomatous Mouse Retinas. PLoS One (2015) 0.87
The longitudinal relation between brain lesion load and atrophy in multiple sclerosis: a 14 year follow up study. J Neurol Neurosurg Psychiatry (2003) 0.87
Brain metabolite proton T2 mapping at 3.0 T in relapsing-remitting multiple sclerosis. Radiology (2010) 0.86
Imaging Surrogates of Disease Activity in Neuromyelitis Optica Allow Distinction from Multiple Sclerosis. PLoS One (2015) 0.86
N-acetylaspartic acid in cerebrospinal fluid of multiple sclerosis patients determined by gas-chromatography-mass spectrometry. J Neurol (2007) 0.85
Corpus callosum index and long-term disability in multiple sclerosis patients. J Neurol (2010) 0.85
Brain atrophy and lesion load are related to CSF lipid-specific IgM oligoclonal bands in clinically isolated syndromes. Neuroradiology (2011) 0.84
Age independently affects myelin integrity as detected by magnetization transfer magnetic resonance imaging in multiple sclerosis. Neuroimage Clin (2014) 0.84
Relationship between brain volume loss and cognitive outcomes among patients with multiple sclerosis: a systematic literature review. Neurol Sci (2015) 0.83
Macroscopic brain architecture changes and white matter pathology in acromegaly: a clinicoradiological study. Pituitary (2009) 0.82
Assessing treatment effects on axonal loss--evidence from MRI monitored clinical trials. J Neurol (2004) 0.82
Relationships between brain water content and diffusion tensor imaging parameters (apparent diffusion coefficient and fractional anisotropy) in multiple sclerosis. Eur Radiol (2005) 0.82
Enlargement of cerebral ventricles as an early indicator of encephalomyelitis. PLoS One (2013) 0.82
Quantification of blood-to-brain transfer rate in multiple sclerosis. Mult Scler Relat Disord (2012) 0.81
Changes observed in multiple sclerosis using magnetic resonance imaging reflect a focal pathology distributed along axonal pathways. J Neurol (2005) 0.81
Treating relapsing-remitting multiple sclerosis: therapy effects on brain atrophy. J Neurol (2015) 0.81
The use of the lumbosacral enlargement as an intrinsic imaging biomarker: feasibility of grey matter and white matter cross-sectional area measurements using MRI at 3T. PLoS One (2014) 0.80
Neuroradiological evaluation of demyelinating disease. Ther Adv Neurol Disord (2013) 0.80
MRI correlates of disability in African-Americans with multiple sclerosis. PLoS One (2012) 0.80
Grey matter magnetization transfer ratio independently correlates with neurological deficit in secondary progressive multiple sclerosis. J Neurol (2009) 0.80
Magnetization transfer ratio in the delayed-release dimethyl fumarate DEFINE study. J Neurol (2014) 0.80
Normalized regional brain atrophy measurements in multiple sclerosis. Neuroradiology (2003) 0.80
In vivo imaging of spinal cord atrophy in neuroinflammatory diseases. Ann Neurol (2014) 0.79
The yearly rate of Relative Thalamic Atrophy (yrRTA): a simple 2D/3D method for estimating deep gray matter atrophy in Multiple Sclerosis. Front Aging Neurosci (2014) 0.79
Diffuse structural and metabolic brain changes in Fabry disease. J Neurol (2006) 0.79
Grey Matter Atrophy in Multiple Sclerosis: Clinical Interpretation Depends on Choice of Analysis Method. PLoS One (2016) 0.78
MRI measures of neurodegeneration in multiple sclerosis: implications for disability, disease monitoring, and treatment. J Neurol (2014) 0.78
Clinical and conventional MRI predictors of disability and brain atrophy accumulation in RRMS. A large scale, short-term follow-up study. J Neurol (2008) 0.78
Regional patterns of grey matter atrophy and magnetisation transfer ratio abnormalities in multiple sclerosis clinical subgroups: a voxel-based analysis study. Mult Scler (2014) 0.78
Association between change in normal appearing white matter metabolites and intrathecal inflammation in natalizumab-treated multiple sclerosis. PLoS One (2012) 0.78
Automated detection of intercellular signaling in astrocyte networks using the converging squares algorithm. J Neurosci Methods (2008) 0.77
Clinical and imaging correlates of the multiple sclerosis impact scale in secondary progressive multiple sclerosis. J Neurol (2011) 0.77
Regional white matter atrophy--based classification of multiple sclerosis in cross-sectional and longitudinal data. AJNR Am J Neuroradiol (2009) 0.77
Segmentation of human brain using structural MRI. MAGMA (2016) 0.77
Increased cortical curvature reflects white matter atrophy in individual patients with early multiple sclerosis. Neuroimage Clin (2014) 0.76
Automated brain volumetrics in multiple sclerosis: a step closer to clinical application. J Neurol Neurosurg Psychiatry (2016) 0.76
Modeling the Presence of Myelin and Edema in the Brain Based on Multi-Parametric Quantitative MRI. Front Neurol (2016) 0.76
An improved FSL-FIRST pipeline for subcortical gray matter segmentation to study abnormal brain anatomy using quantitative susceptibility mapping (QSM). Magn Reson Imaging (2017) 0.76
Systematic imaging review: Multiple Sclerosis. Ann Indian Acad Neurol (2015) 0.75
Outcome Measures in Clinical Trials for Multiple Sclerosis. CNS Drugs (2017) 0.75
Influence of clinical history on MRI interpretation of optic neuropathy. Heliyon (2016) 0.75
Therapeutic efficacy of monthly subcutaneous injection of daclizumab in relapsing multiple sclerosis. Biologics (2016) 0.75
Effect of Fingolimod on Brain Volume Loss in Patients with Multiple Sclerosis. CNS Drugs (2017) 0.75
The Effect of Dimethyl Fumarate on Cerebral Gray Matter Atrophy in Multiple Sclerosis. Neurol Ther (2016) 0.75
Gray Matter Changes in Demyelinating Disease: Correlations with Clinical Scores. Maedica (Buchar) (2015) 0.75
Slowly eroding lesions in multiple sclerosis. Mult Scler (2016) 0.75
Individual Assessment of Brain Tissue Changes in MS and the Effect of Focal Lesions on Short-Term Focal Atrophy Development in MS: A Voxel-Guided Morphometry Study. Int J Mol Sci (2016) 0.75
Neurological software tool for reliable atrophy measurement (NeuroSTREAM) of the lateral ventricles on clinical-quality T2-FLAIR MRI scans in multiple sclerosis. Neuroimage Clin (2017) 0.75
Relevance of the skewness index in DTI exploration of multiple sclerosis. MAGMA (2008) 0.75
Investigating the role of the corpus callosum in regulating motor overflow in multiple sclerosis. J Neurol (2013) 0.75
The Italian Neuroimaging Network Initiative (INNI): enabling the use of advanced MRI techniques in patients with MS. Neurol Sci (2017) 0.75
The Role of T1-Weighted Derived Measures of Neurodegeneration for Assessing Disability Progression in Multiple Sclerosis. Front Neurol (2017) 0.75
MRI: role in optimising treatment. J Neurol (2004) 0.75
Transcranial brain sonography findings related to neuropsychological impairment in multiple sclerosis. J Neurol (2007) 0.75
Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol (2011) 25.66
Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol (2005) 24.22
Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med (2010) 13.82
Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol (2013) 6.18
Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med (2006) 5.20
Further Implications of Off-Label Use of Acetazolamide in the Management of Moyamoya Disease in Japan: Response. Radiology (2017) 4.99
Efficient magnetic cell labeling with protamine sulfate complexed to ferumoxides for cellular MRI. Blood (2004) 4.66
Altered resting state networks in mild cognitive impairment and mild Alzheimer's disease: an fMRI study. Hum Brain Mapp (2005) 4.11
PML in a patient treated with dimethyl fumarate from a compounding pharmacy. N Engl J Med (2013) 4.02
Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis. Hum Mol Genet (2008) 3.93
Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma. J Exp Med (2006) 3.81
Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet (2011) 3.76
A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med (2002) 3.74
Characterization of biophysical and metabolic properties of cells labeled with superparamagnetic iron oxide nanoparticles and transfection agent for cellular MR imaging. Radiology (2003) 3.72
MRI criteria for multiple sclerosis in patients presenting with clinically isolated syndromes: a multicentre retrospective study. Lancet Neurol (2007) 3.47
Retinal nerve fiber layer axonal loss and visual dysfunction in optic neuritis. Ann Neurol (2005) 3.45
Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol (2009) 3.42
Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. Lancet Neurol (2011) 3.16
Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study. Lancet Neurol (2012) 3.15
Comprehensive validation of cardiovascular magnetic resonance techniques for the assessment of myocardial extracellular volume. Circ Cardiovasc Imaging (2013) 3.14
Functional-anatomical validation and individual variation of diffusion tractography-based segmentation of the human thalamus. Cereb Cortex (2004) 3.03
Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch Neurol (2011) 2.75
Chronic cerebrospinal venous insufficiency and multiple sclerosis. Ann Neurol (2010) 2.63
Small vessel disease and general cognitive function in nondisabled elderly: the LADIS study. Stroke (2005) 2.59
Progression of white matter hyperintensities and incidence of new lacunes over a 3-year period: the Leukoaraiosis and Disability study. Stroke (2008) 2.57
Rating scales as outcome measures for clinical trials in neurology: problems, solutions, and recommendations. Lancet Neurol (2007) 2.53
Intracortical lesions in multiple sclerosis: improved detection with 3D double inversion-recovery MR imaging. Radiology (2005) 2.47
Heterogeneity of small vessel disease: a systematic review of MRI and histopathology correlations. J Neurol Neurosurg Psychiatry (2010) 2.44
MRI and the diagnosis of multiple sclerosis: expanding the concept of "no better explanation". Lancet Neurol (2006) 2.44
Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta. Proc Natl Acad Sci U S A (2004) 2.37
Neuroplasticity predicts outcome of optic neuritis independent of tissue damage. Ann Neurol (2010) 2.24
A model of lysosomal metabolism of dextran coated superparamagnetic iron oxide (SPIO) nanoparticles: implications for cellular magnetic resonance imaging. NMR Biomed (2005) 2.20
Magnetic resonance imaging pattern recognition in hypomyelinating disorders. Brain (2010) 2.19
Loss of 'small-world' networks in Alzheimer's disease: graph analysis of FMRI resting-state functional connectivity. PLoS One (2010) 2.12
Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis. Lancet Neurol (2005) 2.10
MRI in multiple sclerosis: current status and future prospects. Lancet Neurol (2008) 2.08
Cortical lesions in multiple sclerosis: combined postmortem MR imaging and histopathology. AJNR Am J Neuroradiol (2005) 2.07
Grey matter volume in a large cohort of MS patients: relation to MRI parameters and disability. Mult Scler (2011) 2.07
Lack of association between antimyelin antibodies and progression to multiple sclerosis. N Engl J Med (2007) 2.06
Labeling of cells with ferumoxides-protamine sulfate complexes does not inhibit function or differentiation capacity of hematopoietic or mesenchymal stem cells. NMR Biomed (2005) 2.02
Quality of life measurement after stroke: uses and abuses of the SF-36. Stroke (2002) 2.00
Motor system activation after subcortical stroke depends on corticospinal system integrity. Brain (2006) 1.99
In vivo magnetic resonance tracking of magnetically labeled cells after transplantation. J Cereb Blood Flow Metab (2002) 1.99
Grey matter pathology in multiple sclerosis. Lancet Neurol (2008) 1.97
Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet (2004) 1.93
Gray matter atrophy is related to long-term disability in multiple sclerosis. Ann Neurol (2008) 1.91
Impact of white matter hyperintensities scoring method on correlations with clinical data: the LADIS study. Stroke (2006) 1.88
Detection and quantification of magnetically labeled cells by cellular MRI. Eur J Radiol (2008) 1.87
Non-invasive mapping of corticofugal fibres from multiple motor areas--relevance to stroke recovery. Brain (2006) 1.85
Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial. Lancet Neurol (2013) 1.84
Precuneus atrophy in early-onset Alzheimer's disease: a morphometric structural MRI study. Neuroradiology (2007) 1.80
Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial. Lancet Neurol (2011) 1.79
The ventral and inferolateral aspects of the anterior temporal lobe are crucial in semantic memory: evidence from a novel direct comparison of distortion-corrected fMRI, rTMS, and semantic dementia. Cereb Cortex (2010) 1.79
Noninvasive MR imaging of magnetically labeled stem cells to directly identify neovasculature in a glioma model. Blood (2004) 1.76
Imaging markers for Alzheimer disease: which vs how. Neurology (2013) 1.76
Unusual variants of Alexander's disease. Ann Neurol (2005) 1.76
Investigating cervical spinal cord structure using axial diffusion tensor imaging. Neuroimage (2002) 1.76
On the etiology of incident brain lacunes: longitudinal observations from the LADIS study. Stroke (2008) 1.75
Early development of multiple sclerosis is associated with progressive grey matter atrophy in patients presenting with clinically isolated syndromes. Brain (2004) 1.71
Cellular magnetic resonance imaging: current status and future prospects. Expert Rev Med Devices (2006) 1.71
Association between pathological and MRI findings in multiple sclerosis. Lancet Neurol (2012) 1.70
Effect sizes can be misleading: is it time to change the way we measure change? J Neurol Neurosurg Psychiatry (2010) 1.70
Combined functional MRI and tractography to demonstrate the connectivity of the human primary motor cortex in vivo. Neuroimage (2003) 1.69
No association of abnormal cranial venous drainage with multiple sclerosis: a magnetic resonance venography and flow-quantification study. J Neurol Neurosurg Psychiatry (2010) 1.68
Improved detection of active multiple sclerosis lesions: 3D subtraction imaging. Radiology (2010) 1.68
Accelerated aging, decreased white matter integrity, and associated neuropsychological dysfunction 25 years after pediatric lymphoid malignancies. J Clin Oncol (2013) 1.67
Whole-brain atrophy rate and CSF biomarker levels in MCI and AD: a longitudinal study. Neurobiol Aging (2008) 1.67
New T2 lesions enable an earlier diagnosis of multiple sclerosis in clinically isolated syndromes. Ann Neurol (2003) 1.66
Structural magnetic resonance imaging in the practical assessment of dementia: beyond exclusion. Lancet Neurol (2002) 1.64
Cannabinoids inhibit neurodegeneration in models of multiple sclerosis. Brain (2003) 1.62
Microbleeds do not affect rate of cognitive decline in Alzheimer disease. Neurology (2012) 1.62
The evolution of prefrontal inputs to the cortico-pontine system: diffusion imaging evidence from Macaque monkeys and humans. Cereb Cortex (2005) 1.61
Magnetic resonance imaging and confocal microscopy studies of magnetically labeled endothelial progenitor cells trafficking to sites of tumor angiogenesis. Stem Cells (2005) 1.61
Overdiagnosis of multiple sclerosis and magnetic resonance imaging criteria. Ann Neurol (2005) 1.61
In vivo trafficking and targeted delivery of magnetically labeled stem cells. Hum Gene Ther (2004) 1.61
Effects of interferon beta-1b on black holes in multiple sclerosis over a 6-year period with monthly evaluations. Arch Neurol (2005) 1.60
Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimer's disease. Alzheimers Dement (2011) 1.59
Patient-based outcomes of cervical dystonia: a review of rating scales. Mov Disord (2004) 1.59
Model-free group analysis shows altered BOLD FMRI networks in dementia. Hum Brain Mapp (2009) 1.59
Disability, atrophy and cortical reorganization following spinal cord injury. Brain (2011) 1.58
Expression of transferrin receptor and ferritin following ferumoxides-protamine sulfate labeling of cells: implications for cellular magnetic resonance imaging. NMR Biomed (2006) 1.58
Patients with Alzheimer disease with multiple microbleeds: relation with cerebrospinal fluid biomarkers and cognition. Stroke (2009) 1.57
Injury markers but not amyloid markers are associated with rapid progression from mild cognitive impairment to dementia in Alzheimer's disease. J Alzheimers Dis (2012) 1.57
Location of brain lesions predicts conversion of clinically isolated syndromes to multiple sclerosis. Neurology (2012) 1.57
A new leukoencephalopathy with brainstem and spinal cord involvement and high lactate. Ann Neurol (2003) 1.57
White matter tract integrity in aging and Alzheimer's disease. Hum Brain Mapp (2009) 1.57
Application of the new McDonald criteria to patients with clinically isolated syndromes suggestive of multiple sclerosis. Ann Neurol (2002) 1.57
Heterogeneity in response to interferon beta in patients with multiple sclerosis: a 3-year monthly imaging study. Arch Neurol (2008) 1.56
Whole-brain atrophy rate and cognitive decline: longitudinal MR study of memory clinic patients. Radiology (2008) 1.56
Intracytoplasmic tagging of cells with ferumoxides and transfection agent for cellular magnetic resonance imaging after cell transplantation: methods and techniques. Transplantation (2003) 1.55
Resting-state fMRI changes in Alzheimer's disease and mild cognitive impairment. Neurobiol Aging (2011) 1.54
Exploring rating scale responsiveness: does the total score reflect the sum of its parts? Neurology (2004) 1.54
Diffusion changes predict cognitive and functional outcome: the LADIS study. Ann Neurol (2013) 1.54
Optic nerve diffusion tensor imaging in optic neuritis. Neuroimage (2005) 1.54